Pharma Equity Group A/S Cl A

PEG · Nasdaq Copenhagen · Healthcare

0.08DKK 0.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −35.4%

Performance

1 month

−6.0%

1 year

−35.4%

3 years, per year

−41.4%

5 years, per year

−33.3%

Largest fall, 3 years

−93.9%

Below the peak now

−99.9%

Volatility, 1 year

78.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.7

Dividend yield

0.0%

Return on equity

−72.0%

Net margin

−187.3%

Market value

14 m USD

Quality, value and trend

Where Pharma Equity Group A/S Cl stands against every Nordic stock today. 100 is best.

Quality14

Profitability and a sound balance sheet over time. Better than 14% of Nordic stocks.

Value4

The price measured against earnings, assets and cash flow. Better than 4% of Nordic stocks.

Trend22

The price development over the past year. Better than 22% of Nordic stocks.

Combined2

Quality, value and trend together. Better than 2% of Nordic stocks.

About Pharma Equity Group A/S Cl

Pharma Equity Group A/S Cl A is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 5 employees.

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis